Related Experiment Video
Updated: Sep 6, 2025
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Effect of Captopril and BQ123 Endothelin-1 Antagonist on Experimentally Induced Hyperlipidemic Nephropathy in Rats
Astha Jaiswal1, Bhupesh Chandra Semwal1, Sonia Singh1
1Department of Pharmacology, Institute of Pharmaceutical Research GLA University, Mathura U.P. 281406, India.
Background:
Kidney disease is a universal public health problem, and epidemiological studies demonstrated that the incidences of chronic kidney disease are increasing day by day. However, the efficiency of currently available drugs on the progression of nephropathy is limited. Therefore, the current research was designed to evaluate the therapeutic efficacy of captopril and BQ123 against hyperlipidemia-induced nephropathy in rats.
Objective:
The objective of this study was to examine the implication of Endothelin-1 in experimentally induced hyperlipidemic nephropathy in rats.
Methods:
Animals were divided into various groups, and the administration of a high-fat diet for six weeks induced hyperlipidemia. After confirmation of hyperlipidemia, treatment was started for the next 14 days. At the end of the experimental period, the animals were sacrificed, and various biochemical parameters and histopathological studies were performed.
Results:
Treatment of both the agents in combination effectively decreased BUN levels, serum creatinine, serum nitrite, and proinflammatory markers and ameliorated the pathological injuries to kidneys.
Conclusion:
Furthermore, both treatments also inhibited oxidative stress and restored the hyperlipidemia-induced reduction in the level of antioxidant enzymes.
Insights
Captopril and BQ123 combination therapy effectively treats hyperlipidemia-induced kidney damage in rats by reducing inflammation and oxidative stress, improving kidney function.
Area of Science:
- Nephrology
- Pharmacology
- Biochemistry
Background:
- Chronic kidney disease (CKD) is a growing global health concern.
- Current treatments for nephropathy show limited efficacy in halting disease progression.
- Hyperlipidemia is a significant risk factor contributing to kidney damage.
Purpose of the Study:
- To investigate the therapeutic potential of captopril and BQ123 in a rat model of hyperlipidemia-induced nephropathy.
- To explore the role of Endothelin-1 in the development of experimentally induced hyperlipidemic nephropathy.
Main Methods:
- Hyperlipidemia was induced in rats via a six-week high-fat diet.
- Animals received treatment with captopril and BQ123 for 14 days post-hyperlipidemia confirmation.
- Biochemical assays and histopathological examinations were conducted to assess kidney damage and function.
Main Results:
- Combined treatment with captopril and BQ123 significantly reduced blood urea nitrogen (BUN) and serum creatinine levels.
- The treatment regimen decreased serum nitrite and pro-inflammatory markers, indicating reduced inflammation.
- Pathological kidney injuries were ameliorated following the combined therapy.
Conclusions:
- Captopril and BQ123 combination therapy demonstrates significant therapeutic efficacy against hyperlipidemia-induced nephropathy.
- The treatment effectively inhibited oxidative stress and restored antioxidant enzyme levels.
- This study highlights the potential of combined captopril and BQ123 as a therapeutic strategy for kidney disease.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:25Antihypertensive Drugs: Direct Renin Inhibitors